Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. (Q38092053)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Statin-associated autoimmune myopathy

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Andrew L Mammen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

1 reference

30 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

477-483

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

26 February 2020

cites work

1 reference

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

21 January 2018

1 reference

Narrative review: statin-related myopathy

21 January 2018

1 reference

Statin myopathy: incidence, risk factors, and pathophysiology

21 January 2018

1 reference

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy

21 January 2018

1 reference

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy

21 January 2018

1 reference

Statin myopathy: a review of recent progress

21 January 2018

1 reference

The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care

21 January 2018

1 reference

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases

21 January 2018

1 reference

A comprehensive description of muscle symptoms associated with lipid-lowering drugs.

21 January 2018

1 reference

Prevalence of musculoskeletal pain and statin use.

21 January 2018

1 reference

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients

21 January 2018

1 reference

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006

21 January 2018

1 reference

Outcomes in 45 patients with statin-associated myopathy

21 January 2018

1 reference

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy

21 January 2018

1 reference

Does simvastatin cause more myotoxicity compared with other statins?

21 January 2018

1 reference

SLCO1B1 variants and statin-induced myopathy

21 January 2018

1 reference

Genetic risk factors associated with lipid-lowering drug-induced myopathies

21 January 2018

1 reference

Genetic determinants of statin intolerance

21 January 2018

1 reference

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin

21 January 2018

1 reference

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

21 January 2018

1 reference

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

Association between statin-associated myopathy and skeletal muscle damage

21 January 2018

1 reference

Fluvastatin-induced dermatomyositis

21 January 2018

1 reference

Simvastatin-induced dermatomyositis

21 January 2018

1 reference

Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects

21 January 2018

1 reference

Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis

21 January 2018

1 reference

Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

21 January 2018

1 reference

Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MUS.23854

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23519993%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference